Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith R. Leonard unloaded 1,743 shares of the stock on the open market in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $36.58, for a total transaction of $63,758.94. The sale was disclosed in a document filed with the SEC, which is available at this link.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.78% during mid-day trading on Tuesday, hitting $37.05. 155,411 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a one year low of $22.88 and a one year high of $56.36. The stock’s 50-day moving average is $33.55 and its 200-day moving average is $39.76. The company’s market cap is $839.4 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($3.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.67) by $2.51. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-3.33 earnings per share for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.